Overview

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized controlled phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with rheumatoid arthritis.
Phase:
PHASE1
Details
Lead Sponsor:
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborator:
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.